首页 文献索引 SCI期刊 AI助手
登录 注册
首页 正文

Internal medicine (Tokyo, Japan). 2025 Apr 12. doi: 10.2169/internalmedicine.5362-25 Q41.02024

Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment

一名系统性红斑狼疮患者在使用安尼鲁单抗和霉酚酸酯治疗两年内发生弥漫大B细胞淋巴瘤 翻译改进

Takuya Matsubara  1, Masahiro Takita  1, Ikue Sekai  1, Naoya Omaru  1, Natsuki Okai  1, Masahiro Morita  1, Ken Kamata  1, Kosuke Minaga  1, Tomohiro Watanabe  1, Masatoshi Kudo  1

作者单位 +展开

作者单位

  • 1 Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan.
  • DOI: 10.2169/internalmedicine.5362-25 PMID: 40222946

    摘要 中英对照阅读

    Anifrolumab is a newly developed biological agent for patients with moderate-to-severe systemic lupus erythematosus (SLE). Anifrolumab neutralizes the signaling pathways mediated by type I interferons (IFNs), which are involved in viral clearance and anticancer immunity. Although susceptibility to viral infections has been reported in patients treated with anifrolumab, whether anifrolumab treatment increases the cancer risk in patients with SLE is unknown. We herin report a case of SLE that manifested as aggressive diffuse large B-cell lymphoma (DLBCL) after treatment with anifrolumab. The neutralization of type I IFNs by anifrolumab may promote the development of DLBCL owing to defective anticancer immunity.

    Keywords: Anifrolumab; Malignant lymphoma; SLE.

    Keywords:diffuse large b cell lymphoma; systemic lupus erythematosus; anifrolumab; mycophenolate mofetil

    安福罗单抗是一种用于治疗中度至重度系统性红斑狼疮(SLE)的新型生物制剂。安福罗单抗可以中和由I型干扰素(IFN)介导的信号通路,而这些通路与病毒清除和抗癌免疫有关。虽然有报道显示使用安福罗单抗治疗的患者易受病毒感染,但尚不清楚安福罗单抗治疗是否增加了SLE患者的癌症风险。我们在此报告一例在使用安福罗单抗治疗后出现侵袭性弥漫大B细胞淋巴瘤(DLBCL)的SLE病例。由于抗癌免疫功能缺陷,安福罗单抗对I型IFN的中和作用可能促进了DLBCL的发展。

    关键词:安福罗单抗;恶性淋巴瘤;SLE。

    关键词:弥漫性大B细胞淋巴瘤; 系统性红斑狼疮; 安尼福隆马布; 霉酚酸酯

    翻译效果不满意? 用Ai改进或 寻求AI助手帮助 ,对摘要进行重点提炼
    Copyright © Internal medicine (Tokyo, Japan). 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Internal medicine

    缩写:INTERNAL MED

    ISSN:0918-2918

    e-ISSN:1349-7235

    IF/分区:1.0/Q4

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment